Rapid Readouts: Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naïve Chronic Lymphocytic Leukemia: ELEVATE-TN 4-Year Follow-up

July 8, 2021 | Alan Skarbnik, MD

Alan Skarbnik, MD, presents data from the 2021 American Society of Clinical Oncology annual meeting on the ELEVATE-TN trial four-year follow up of chronic lymphocytic leukemia patients treated with acalabrutinib ± obinutuzumab vs obinutuzumab + chlorambucil